[HTML][HTML] Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

GA Kim, JH Moon, W Kim - Clinical and molecular hepatology, 2023 - ncbi.nlm.nih.gov
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns
due to its inherent disadvantages of using exclusionary diagnostic criteria and the …

Steatotic liver disease: metabolic dysfunction, alcohol, or both?

K Staufer, RE Stauber - Biomedicines, 2023 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of
them accounting for fatty liver disease (FLD), are among the most common chronic liver …

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis …

P Danpanichkul, K Suparan, P Dutta, C Kaeosri… - Metabolism, 2024 - Elsevier
Objective Metabolic dysfunction-associated steatotic liver disease (MASLD) and
cardiometabolic conditions affect populations across economic strata. Nevertheless, there …

[HTML][HTML] A global action agenda for turning the tide on fatty liver disease

JV Lazarus, HE Mark, AM Allen, JP Arab, P Carrieri… - Hepatology, 2024 - journals.lww.com
Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda
developed by care providers, clinical researchers, and public health and policy experts …

[HTML][HTML] Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

L Tao, X Yang, C Ge, P Zhang, W He, X Xu, X Li… - Cell Metabolism, 2024 - cell.com
The complex etiological factors associated with metabolic dysfunction-associated fatty liver
disease (MAFLD), including perturbed iron homeostasis, and the unclear nature by which …

Food inequity and insecurity and MASLD: burden, challenges, and interventions

S Zelber-Sagi, P Carrieri, JM Pericàs… - Nature Reviews …, 2024 - nature.com
Liver disease prevalence, severity, outcomes and hepatic risk factors (for example,
unhealthy diet) are heavily affected by socioeconomic status and food insecurity. Metabolic …

Opportunities and challenges following approval of resmetirom for MASH liver disease

JV Lazarus, D Ivancovsky Wajcman, HE Mark… - Nature Medicine, 2024 - nature.com
Opportunities and challenges following approval of resmetirom for MASH liver disease | Nature
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …

Steatotic liver disease

M Israelsen, S Francque, EA Tsochatzis, A Krag - The Lancet, 2024 - thelancet.com
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …

[HTML][HTML] A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Liver Disease (MASLD): Another matter to face through a holistic …

M Meroni, M Longo, E Paolini, P Dongiovanni - Journal of Advanced …, 2024 - Elsevier
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most
common chronic hepatic disorder worldwide in both adults and children. It is well …

Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria

LA Díaz, JV Lazarus, E Fuentes-López… - Communications …, 2024 - nature.com
Introduction The 2023 nomenclature defined criteria for steatotic liver disease (SLD),
including metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease …